Zacks Investment Research upgraded shares of Collegium Pharmaceutical (NASDAQ:COLL) from a hold rating to a buy rating in a research report sent to investors on Monday. They currently have $26.00 price objective on the specialty pharmaceutical company’s stock.
According to Zacks, “Collegium Pharmaceutical Inc. is a specialty pharmaceutical company. It develops and commercializes prescription and over-the-counter pharmaceuticals for the treatment of central nervous system, respiratory and skin related disorders. The Company’s product candidate consists of COL-195, COL-196, COL-171, COL-003 and COL-172 which are in different clinical trial. It developed a formulation platform technology, DETERx, for the treatment of chronic pain. Collegium Pharmaceutical Inc. is based in CUMBERLAND, United States. “
Other equities research analysts also recently issued reports about the company. HC Wainwright lifted their target price on Collegium Pharmaceutical from $21.00 to $33.00 and gave the stock a buy rating in a report on Thursday, March 8th. Janney Montgomery Scott set a $26.00 price objective on Collegium Pharmaceutical and gave the company a buy rating in a research note on Tuesday, February 6th. BidaskClub raised Collegium Pharmaceutical from a hold rating to a buy rating in a research note on Thursday, February 15th. Jefferies Group raised their price objective on Collegium Pharmaceutical to $32.00 and gave the company a buy rating in a research note on Monday, February 12th. Finally, Piper Jaffray set a $33.00 price objective on Collegium Pharmaceutical and gave the company a buy rating in a research note on Monday, February 12th. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The stock has an average rating of Buy and a consensus target price of $30.83.
Shares of COLL stock opened at $25.43 on Monday. Collegium Pharmaceutical has a fifty-two week low of $7.37 and a fifty-two week high of $29.90.
Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Wednesday, March 7th. The specialty pharmaceutical company reported ($0.54) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.56) by $0.02. The business had revenue of $10.79 million during the quarter, compared to the consensus estimate of $9.88 million. Collegium Pharmaceutical had a negative return on equity of 73.00% and a negative net margin of 262.91%. Collegium Pharmaceutical’s revenue was up 728.4% on a year-over-year basis. research analysts predict that Collegium Pharmaceutical will post -0.74 EPS for the current fiscal year.
In other Collegium Pharmaceutical news, Chairman Michael Thomas Heffernan sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 23rd. The stock was sold at an average price of $25.01, for a total value of $500,200.00. Following the completion of the sale, the chairman now owns 535,395 shares of the company’s stock, valued at $13,390,228.95. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 25.76% of the company’s stock.
Several large investors have recently made changes to their positions in COLL. JPMorgan Chase & Co. purchased a new position in shares of Collegium Pharmaceutical during the third quarter valued at approximately $192,000. Wells Fargo & Company MN boosted its position in shares of Collegium Pharmaceutical by 12.8% during the third quarter. Wells Fargo & Company MN now owns 45,254 shares of the specialty pharmaceutical company’s stock valued at $475,000 after buying an additional 5,136 shares during the last quarter. Benjamin F. Edwards & Company Inc. boosted its position in shares of Collegium Pharmaceutical by 87.5% during the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 7,500 shares of the specialty pharmaceutical company’s stock valued at $138,000 after buying an additional 3,500 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its position in shares of Collegium Pharmaceutical by 13.5% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 51,119 shares of the specialty pharmaceutical company’s stock valued at $944,000 after buying an additional 6,083 shares during the last quarter. Finally, Acadian Asset Management LLC purchased a new position in shares of Collegium Pharmaceutical during the fourth quarter valued at approximately $176,000. 86.39% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY WARNING: This article was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another site, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/20/collegium-pharmaceutical-coll-upgraded-to-buy-at-zacks-investment-research.html.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.
Get a free copy of the Zacks research report on Collegium Pharmaceutical (COLL)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.